{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
BridgeBio Pharma, Inc.
BridgeBio Pharma Hits New 52-Week High of $57.49, Up 103.49%
BridgeBio Pharma, Inc. achieved a new 52-week high of USD 57.49 on October 15, 2025, reflecting a substantial increase over the past year. With a market capitalization of USD 10,715 million, the company has a strong return on equity but is currently loss-making, as indicated by its financial metrics.
BridgeBio Pharma Hits New 52-Week High of $57.47, Up 103%
BridgeBio Pharma, Inc. achieved a new 52-week high of USD 57.47 on October 14, 2025, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant growth over the past year, with a notable return on equity and unique financial metrics despite being loss-making.
BridgeBio Pharma Hits New 52-Week High of $56.24, Up 101% Yearly
BridgeBio Pharma, Inc. achieved a new 52-week high of USD 56.24 on October 13, 2025, reflecting a substantial increase over the past year. The company, with a market capitalization of USD 10,715 million, has shown strong financial metrics despite being currently loss-making and navigating a competitive industry landscape.
BridgeBio Pharma Hits New 52-Week High of $55.33, Up 98.71%
BridgeBio Pharma, Inc. achieved a new 52-week high on October 8, 2025, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has seen significant growth over the past year, with a notable return on equity, despite currently operating at a loss and lacking a dividend yield.
BridgeBio Pharma Hits New 52-Week High of $55.13, Up 94.83%
BridgeBio Pharma, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector with a notable increase over the past year. The company, with a market capitalization of USD 10,715 million, is currently loss-making but has demonstrated impressive financial metrics.
BridgeBio Pharma Hits New 52-Week High of $54.64, Up 96.23%
BridgeBio Pharma, Inc. recently achieved a new 52-week high, reflecting a substantial increase in its stock price over the past year. The company, operating in the Pharmaceuticals & Biotechnology sector, has shown strong financial metrics despite being loss-making, with a notable market capitalization and significant upward movement from its previous low.
BridgeBio Pharma, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
BridgeBio Pharma, Inc. has recently revised its evaluation amid changing market dynamics. The company has shown remarkable performance over the past year, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, while the stock has reached a 52-week high, reflecting strong momentum and strategic positioning in biotechnology.
Is BridgeBio Pharma, Inc. technically bullish or bearish?
As of October 3, 2025, BridgeBio Pharma, Inc. has a mildly bullish technical trend, supported by bullish indicators in MACD and Bollinger Bands, despite a mildly bearish KST signal, and it has significantly outperformed the S&P 500 year-to-date and over the past year.
Is BridgeBio Pharma, Inc. technically bullish or bearish?
As of October 3, 2025, BridgeBio Pharma, Inc. has a mildly bullish technical trend, supported by strong monthly indicators and significant outperformance against the S&P 500, with year-to-date and one-year returns of 92.64% and 106.24%, respectively.
Is BridgeBio Pharma, Inc. technically bullish or bearish?
As of October 3, 2025, BridgeBio Pharma, Inc. shows a mildly bullish trend overall, supported by bullish Bollinger Bands and moving averages, despite mixed signals from the MACD and KST, and has significantly outperformed the S&P 500 with year-to-date and one-year returns of 92.64% and 106.24%, respectively.
BridgeBio Pharma, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
BridgeBio Pharma, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock has shown impressive performance, achieving a 104.45% return over the past year, significantly outperforming the S&P 500. Its three-year return stands at 448.19%, underscoring the company's growth potential in the pharmaceuticals sector.
Is BridgeBio Pharma, Inc. technically bullish or bearish?
As of September 26, 2025, BridgeBio Pharma, Inc. exhibits a bullish technical trend supported by positive MACD indicators and strong performance, significantly outperforming the S&P 500 with a 104.45% return over the past year.
Is BridgeBio Pharma, Inc. technically bullish or bearish?
As of September 26, 2025, BridgeBio Pharma, Inc. shows a bullish technical trend supported by positive MACD indicators and moving averages, despite mixed signals from Dow Theory, with strong year-to-date and one-year returns of 82.40% and 104.45%, respectively.
Is BridgeBio Pharma, Inc. technically bullish or bearish?
As of September 26, 2025, BridgeBio Pharma, Inc. has a bullish technical trend supported by positive MACD indicators and strong year-to-date returns of 82.40%, significantly outperforming the S&P 500.
Is BridgeBio Pharma, Inc. technically bullish or bearish?
As of June 6, 2025, BridgeBio Pharma, Inc. shows a strong bullish trend supported by positive technical indicators, outperforming the S&P 500 with a year-to-date return of 94.35% compared to 12.22%.
Is BridgeBio Pharma, Inc. overvalued or undervalued?
BridgeBio Pharma, Inc. is currently classified as risky due to its overvaluation indicated by negative valuation ratios, despite a strong year-to-date stock performance of 94.35%, which significantly exceeds the S&P 500's 12.22% return.
Is BridgeBio Pharma, Inc. overvalued or undervalued?
As of November 7, 2019, BridgeBio Pharma, Inc. is considered overvalued and risky due to unfavorable financial metrics, including a negative Price to Book Value of -4.59 and an EV to Sales ratio of 73.65, despite a strong stock performance relative to the S&P 500.
Is BridgeBio Pharma, Inc. technically bullish or bearish?
As of June 6, 2025, BridgeBio Pharma, Inc. has a bullish trend supported by strong indicators like a bullish MACD and Bollinger Bands, despite a mildly bearish KST, and has significantly outperformed the S&P 500.
Who are in the management team of BridgeBio Pharma, Inc.?
As of March 2022, the management team of BridgeBio Pharma, Inc. includes Dr. Neil Kumar (CEO), Dr. Charles Homcy (Chairman of Pharmaceuticals), Dr. Richard Scheller (Chairman of R&D), and several independent directors: Dr. Eric Aguiar, Ms. Jennifer Cook, Mr. Ronald Daniels, Andrew Lo, and Mr. James Momtazee. This team offers a diverse range of expertise.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
